Acutaas Chemicals profit surges 70% in Q1FY27 on margin expansion
Acutaas Chemicals posted a 70.4% increase in Q1FY27 net profit to ₹750 million, supported by robust revenue growth of 59.1% to ₹3,297 million. The performance was led by the Advance Intermediates segment, which grew 76.5%, offsetting a decline in Specialty Chemicals. The company also disclosed regulatory inspections and a strategic dilution in its electrolyte subsidiary.
*this image is generated using AI for illustrative purposes only.
Acutaas Chemicals reported a consolidated net profit of ₹750 million for the first quarter ended June 30, 2026, marking a 70.4% year-on-year increase from ₹440 million in the corresponding period of FY26. The speciality chemicals manufacturer’s revenue from operations rose 59.1% to ₹3,297 million, driven by higher volumes in its pharma intermediates segment and improved operational efficiency. Profit after tax (PAT) margins expanded to 22.7% from 21.2% last year, reflecting strong operating leverage despite a decline in other income.
The Board of Directors approved the unaudited standalone and consolidated financial results during a meeting held on July 24, 2026. The results were reviewed by the Audit Committee and subjected to a limited review by statutory auditors M/s Maheshwari & Co., Chartered Accountants. The company disclosed compliance with Regulation 33 and Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. An accompanying investor presentation was filed with the Bombay Stock Exchange and National Stock Exchange of India Limited.
Financial Performance Highlights
Consolidated revenue from operations stood at ₹3,297 million in Q1FY27, compared to ₹2,072 million in Q1FY26. Gross profit surged 73.0% to ₹1,909 million, pushing gross margins up by 466 basis points to 57.9%. EBITDA more than doubled to ₹1,131 million from ₹509 million, with EBITDA margins improving to 34.3% from 24.6%. Total income reached ₹3,314.76 million.
| Metric (₹ in millions) | Q1FY27 | Q1FY26 | YoY Change |
|---|---|---|---|
| Revenue from Operations | 3,297 | 2,072 | +59.1% |
| Gross Profit | 1,909 | 1,103 | +73.0% |
| EBITDA | 1,131 | 509 | +122.1% |
| Profit After Tax | 750 | 440 | +70.4% |
On a standalone basis, Acutaas Chemicals reported a net profit of ₹759 million, up 70.2% from ₹446.5 million in Q1FY26. Standalone revenue from operations grew 56.5% to ₹3,224.1 million. Earnings per share (basic) increased to ₹9.07 on a consolidated basis and ₹9.27 on a standalone basis, compared to ₹5.41 and ₹5.45 respectively in the previous year’s quarter.
Segmental Revenue Breakdown
The growth was primarily fueled by the Advance Intermediates segment, which saw revenue jump 76.5% to ₹2,927 million from ₹1,658 million in Q1FY26. In contrast, the Specialty Chemicals segment experienced a decline of 10.6%, with revenue falling to ₹370 million from ₹414 million. Naresh Patel, Executive Chairman & Managing Director, attributed the overall growth to the agility of the business model and strong demand in contract development and manufacturing organization (CDMO) services.
| Segment | Q1FY26 (₹ Mn.) | Q1FY27 (₹ Mn.) | YoY Growth (%) |
|---|---|---|---|
| Advance Intermediates | 1,658 | 2,927 | 76.5% |
| Specialty Chemicals | 414 | 370 | (10.6%) |
| Total | 2,072 | 3,297 | 59.1% |
Operational Developments and Certifications
During the quarter, Acutaas Chemicals Electrolytes Private Limited (ACEPL), a subsidiary, issued equity shares on a partly paid-up basis to A.R.Z Pharma Ltd. This transaction diluted the parent company’s stake in ACEPL from 100% to 90%, effective May 19, 2026. ACEPL remains a subsidiary, with no change in control reported by management.
Additionally, the Central Goods & Service Tax and Central Excise (CGST & CE), Anti-Evasion Department, conducted inspection and search proceedings at the company’s registered office and manufacturing facility in Surat, Gujarat, on June 22–23, 2026. Management stated that based on information available as of the board meeting date, they do not expect any material impact on the financial position or results of operations.
The company also announced it has been certified as a Great Place to Work and received the Responsible Care certification from the Indian Chemical Council, reaffirming its commitment to safety, health, and environmental performance standards.
What the Numbers Show
The divergence between revenue growth (59%) and expense growth highlights improved operating leverage for Acutaas Chemicals in Q1FY27. While other income dropped sharply due to lower interest income and foreign exchange gains, the core operating profit expanded disproportionately, indicating stronger pricing power or cost containment in its speciality chemicals business. The dilution in ACEPL introduces a non-controlling interest component but does not alter strategic control, suggesting a partnership model aimed at scaling electrolyte production capabilities without full capital outlay. Naresh Patel expressed confidence in delivering 25% revenue growth for the full year with stable margins.
Historical Stock Returns for Acutaas Chemicals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -4.56% | -7.89% | +0.73% | +99.66% | +178.07% | +606.14% |
How might the 10.6% decline in the Specialty Chemicals segment impact Acutaas's long-term diversification strategy and revenue stability?
What specific operational efficiencies or pricing strategies enabled gross margins to expand by 466 basis points despite rising input costs in the chemical sector?
Could the recent tax inspection proceedings in Surat lead to any retrospective liabilities or compliance changes that might affect future cash flows?
20
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
